Ovarian Cancer This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest news and research items in this category.

Zinc protoporphyrin suppresses cancer cell viability through a heme oxygenase-1-independent mechanism: The involvement of the Wnt/β-catenin signaling pathway.
We examined this hypothesis by altering cellular levels of HO-1 in human ovarian (A2780) and prostate cancer (DU145) cells and found that ZnPP inhibits cancer cell viability through an HO-1-independent mechanism. Neither over-expression nor knockdown of HO-1 significantly alters ZnPP's cytotoxicity in human cancer cells, indicating that HO-1 does not mediate ZnPP's inhibitory effect on cancer cell growth. Consistent with these observations, tin protoporphyrin (SnPP), a well-established HO-1 inhibitor, was found to be much less cytotoxic than ZnPP, and docosahexaenoic acid (DHA), an HO-1 inducer, enhanced ZnPP's cytotoxicit...
Source: Biochemical Pharmacology - May 24, 2013 Category: Drugs & Pharmacology Authors: Wang S, Avery JE, Hannafon BN, Lind SE, Ding WQ Tags: Biochem Pharmacol Source Type: research

Salpingectomy With Hysterectomy May Reduce Cancer RiskSalpingectomy With Hysterectomy May Reduce Cancer Risk
Removing the fallopian tubes at the time of hysterectomy could reduce long-term risk for serous ovarian cancer and might have short-term benefits, report researchers. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Brad and Angelina: What Does Unconditional Love Look Like?
In sickness and in health, how do you show support?read more (Source: Psychology Today Relationships Center)
Source: Psychology Today Relationships Center - May 24, 2013 Category: Psychiatry & Psychology Authors: Jane Greer, Ph.D. Tags: Health Relationships acknowledgement Angelina Jolie brad pitt BRCA1 brca1 gene breast center courage double mastectomy ed piece harder time high risk judgments lotus medical procedures New York Times ovarian cancer ovar Source Type: news

Reality check: there is no such thing as a miracle food.
Abstract A recent episode of the Dr. Oz Show suggested endive, red onion, and sea bass as foods that can decrease the risk of ovarian cancer by up to 75%. However, the scientific evidence supporting these recommendations is limited. This commentary discusses some of the concerns related to the promotion of "miracle foods" by the media. Nutritional scientists and epidemiologists should be cognizant of the public health messages that are taken from their individual studies and not sensationalize the findings of a single study. PMID: 23441603 [PubMed - in process] (Source: Nutrition and Cancer)
Source: Nutrition and Cancer - May 24, 2013 Category: Cancer & Oncology Authors: Inoue-Choi M, Oppeneer SJ, Robien K Tags: Nutr Cancer Source Type: research

A correlation between altered O-GlcNAcylation, migration and with changes in E-cadherin levels in ovarian cancer cells.
In this study, we modeled four diverse ovarian cancer cells and investigated the effects of O-GlcNAcylation on ovarian cancer cell migration. We found that total O-GlcNAcylation level was elevated in HO-8910PM cells compared to OVCAR3 cells. Additionally, through altering the total O-GlcNAcylation level by OGT silencing or OGA inhibition, we found that the migration of OVCAR3 cells was dramatically enhanced by PUGNAc and Thiamet G treatment, and the migration ability of HO-8910PM cells was significantly inhibited by OGT silencing. Furthermore, we also found that the expression of E-cadherin, an O-GlcNAcylated protein in ov...
Source: Experimental Cell Research - May 24, 2013 Category: Cytology Authors: Jin FZ, Yu C, Zhao DZ, Wu MJ, Yang Z Tags: Exp Cell Res Source Type: research

Metabolic changes during ovarian cancer progression as targets for sphingosine treatment.
Abstract Tumor cells often exhibit an altered metabolic phenotype. However, it is unclear as to when this switch takes place in ovarian cancer, and the potential for these changes to serve as therapeutic targets in clinical prevention and intervention trials. We used our recently developed and characterized mouse ovarian surface epithelial (MOSE) cancer progression model to study metabolic changes in distinct disease stages. As ovarian cancer progresses, complete oxidation of glucose and fatty acids were significantly decreased, concurrent with increases in lactate excretion and (3)H-deoxyglucose uptake by the late...
Source: Experimental Cell Research - May 24, 2013 Category: Cytology Authors: Anderson AS, Roberts PC, Frisard MI, McMillan RP, Brown TJ, Lawless MH, Hulver MW, Schmelz EM Tags: Exp Cell Res Source Type: research

Young girl with abnormal behavior: Anti-N-Methyl-D-Aspartate receptor immune encephalitis
We report a case of a 17 years old girl with Anti NMDARE who was initially misdiagnosed as Functional psychosis, Neuroleptic Malignant Syndrome and Sepsis syndrome. To the best of our knowledge, this is only the second case of anti NMDARE being reported from India. This case report underscores the need for a greater awareness of this entity across multiple specialties, e.g., general medicine, psychiatry and neurology, to ensure a heightened diagnostic suspicion, which can lead to timely diagnosis and adequate therapy of this treatable disease. (Source: Annals of Indian Academy of Neurology)
Source: Annals of Indian Academy of Neurology - May 24, 2013 Category: Neurology Authors: Vinit SuriSushma SharmaRohan GuptaNilesh JadhaoKunal Suri Source Type: research

Ovarian cancer emerging subtypes: Role of oxidative stress and fibrosis in tumour development and response to treatment.
Abstract Epithelial ovarian cancer is a silent disease of usually late diagnosis and poor prognosis. Currently treatment options are limited and mainly consist of surgery followed by taxol- and platinum-based chemotherapy. Patient response to treatment is difficult to predict and there is a serious need for anticipating tumour response and orientating medical choices. In that aim, recent researches have focused on molecular aspects of ovarian tumours that could help patient stratification. We review here published discoveries in that field. We emphasize that signatures, defined by combining miRNA and transcriptomic...
Source: The International Journal of Biochemistry and Cell Biology - May 23, 2013 Category: Biochemistry Authors: Batista L, Gruosso T, Mechta-Grigoriou F Tags: Int J Biochem Cell Biol Source Type: research

Breast Cancer Screening, Risk, and Options for High-Risk Women
We speak with two experts to discuss breast cancer risk, genetics, and prevention options available to women at high risk of developing breast and ovarian cancer. (Source: Cancer Network)
Source: Cancer Network - May 23, 2013 Category: Cancer & Oncology Source Type: news

Cervical Cancer Studies Take Center StageCervical Cancer Studies Take Center Stage
Dr. Maurie Markman predicts that ASCO 2013 will be a hotbed for gynecologic cancer research, including highly anticipated studies in ovarian cancer and plenary-featured studies in cervical cancer. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Fighting Ovarian Cancer With Gold Nanoparticles
Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the current online issue of the Journal of Biological Chemistry... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2013 Category: Consumer Health News Tags: Ovarian Cancer Source Type: news

Medicine, mutilation or stock manipulation? The strange case of Angelina Jolie
ANH-Intl speculates on what might be going on behind the scenes (Source: Alliance for Natural Health)
Source: Alliance for Natural Health - May 22, 2013 Category: Complementary Medicine Authors: Sophie Tags: Angelina Jolie breast cancer europe international mastectomy oophorectomy ovarian cancer Source Type: news

Identification of miRNA modulators to PARP inhibitor response.
Abstract Based on the principle of synthetic lethality, PARP inhibitors have been shown to be very effective in killing cells deficient in homologous recombination (HR), such as those bearing mutations in BRCA1/2. However, questions regarding their wider use persist and other determinants of responsiveness to PARP inhibitor remain to be fully explored. MicroRNAs (miRNAs) are small non-coding RNAs, which serve as post-transcriptional regulators of gene expression and are involved in a wide variety of cellular processes, including the DNA damage response (DDR). However, little is known about whether miRNAs might infl...
Source: DNA Repair - May 22, 2013 Category: Genetics & Stem Cells Authors: Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A Tags: DNA Repair (Amst) Source Type: research

Use of immunohistochemistry in the diagnosis of problematic breast lesions
This article reviews the common uses of immunohistochemistry in diagnostic breast pathology. It is important to be aware of the limitations of individual antibodies. Such problems can often be overcome by using panels of antibodies. Quality control is also essential: internal and external controls should show appropriate staining. Immunohistochemistry must be interpreted in combination with the morphology seen on H&E sections. Myoepithelial markers, such as smooth muscle actin, smooth muscle myosin heavy chain and p63, are useful for distinguishing invasive carcinoma from sclerosing lesions and ductal carcinoma in situ...
Source: Journal of Clinical Pathology - May 22, 2013 Category: Pathology Authors: Lee, A. H. S. Tags: Immunology (including allergy), Breast cancer, Skin cancer, Gynecological cancer, Lung cancer (oncology), Lung cancer (respiratory medicine), Dermatology Review Source Type: research

Mayo Clinic: How Gold Nanoparticles Can Help Fight Ovarian Cancer
Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - May 21, 2013 Category: Hospital Management Authors: Mayo Clinic Source Type: news

Mayo Clinic: How Gold Nanoparticles Can Help Fight Ovarian Cancer
Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 21, 2013 Category: Databases & Libraries Authors: Mayo Clinic Source Type: news

More than 15,000 patients are dying in Britain every year as a result of cancer treatments rather than the disease itself, warns Lord Saatchi
The advertising mogul has been campaigning for law changes to enable doctors to carry out alternative treatments since his wife, novelist Josephine Hart, died from a form of ovarian cancer in 2011. (Source: the Mail online | Health)
Source: the Mail online | Health - May 21, 2013 Category: Consumer Health News Source Type: news

Mayo Clinic: How gold nanoparticles can help fight ovarian cancer
(Mayo Clinic) Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why, and determined how to make the nanoparticles effective against ovarian cancer cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 21, 2013 Category: Global & Universal Source Type: news

Angelina Jolie and the One Percent
After learning that she had inherited a mutation on one of the so-called breast cancer genes, actress Angelina Jolie decided to have a double mastectomy to reduce her risk of developing breast cancer. She also plans to have her ovaries removed to reduce her risk of ovarian cancer. It may sound like a drastic measure, but mutations on the breast cancer genes ( BRCA1 and BRCA2 ) increase the overall risk of developing several cancers, including prostate, pancreatic, testicular, ovarian, and breast. On average, a woman with a BRCA1 mutation (the one Jolie has) has a 65 percent risk of developing breast cancer and a 39 percent...
Source: Scientific American - Official RSS Feed - May 20, 2013 Category: Science Tags: Health,More Science Source Type: research

Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels
Background: Chemotherapy-induced amenorrhea (CIA) is one of the most frequent therapy-related adverse events observed in patients who have undergone chemotherapy . Although the characteristics of CIA have been studied in Western countries, little is known about CIA in Asian women, particularly those with breast cancer. We conducted a retrospective analysis to assess the characteristics and influencing factors of CIA and its association with menopause in Chinese women who underwent adjuvant chemotherapy for early-stage breast cancer. Methods: Seventy-three premenopausal women who underwent adjuvant chemotherapy for early st...
Source: World Journal of Surgical Oncology - May 20, 2013 Category: Cancer & Oncology Authors: Kexin MengWei TianMeiqi ZhouHailong ChenYongchuan Deng Source Type: research

Pancreatic mucinous cystic neoplasm with sarcomatous stroma metastasizing to liver: a case report and review of literature
We report a case of mucinous cystic neoplasm of pancreas with sarcomatous stroma metastasizing to the liver. The tumor occurred in a male patient aged 46 years. Symptoms included persistent epigastric and right upper quadrant pain. Radiographically, the pancreas contained four large cystic masses located in the neck, body, and tail. Histologically, the cysts were lined with benign, mucinous epithelium with underlying bland, storiform, ovarian-like stroma. An undifferentiated focally hyalinized, sarcomatous stroma composed of bland spindle cells showing short fascicular growth pattern and focal nuclear palisading was associ...
Source: World Journal of Surgical Oncology - May 20, 2013 Category: Cancer & Oncology Authors: Michael WayneDeniz GurGil AscunceBen AbodessaViolette Ghali Source Type: research

Video: Young Innovators: Teen tackles cancer diagnosis
After his close friend died from pancreatic cancer, 16-year-old Jack Andraka unleashed his hyper-drive intellect on preventing more cancer deaths. And as Jim Axelrod reports, the teen created a much faster and far cheaper detection method for pancreatic, ovarian and lung cancer. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 18, 2013 Category: Consumer Health News Source Type: news

Among Patients Carrying BRCA Mutations, PARP Inhibitor Shows Activity In Pancreatic, Prostate Cancers
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 18, 2013 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news

Angelina Jolie Will Have Ovaries Removed to Lower Chances of Cancer: Report
Actress has already had double mastectomy due to gene linked to high risk for breast, ovarian cancer (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - May 17, 2013 Category: Cancer & Oncology Source Type: news

Angelina Jolie’s Double Mastectomy: Q&A
WebMD Medical News By Kathleen Doheny Reviewed by Michael W. Smith, MD May 14, 2013 — Actress and activist Angelina Jolie’s recent decision to have a preventive double mastectomy highlights the difficult choices facing women who find out they have a high risk for breast cancer because of their genes. Although relatively rare, mutations in the BRCA1 and BRCA2 genes raise the risk of breast cancer by as much as 80%, experts say. The mutations also raise the risk of ovarian cancer. Jolie describes in a New York Times op-ed piece why she decided to go through with the surgery. At 37, the mother of six wants to sta...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 17, 2013 Category: Consumer Health News Authors: mreal197 Tags: WebMD News Source Type: news

Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain)
Conclusions: In this study we report the BRCA1 and BRCA2 spectrum of mutations and their geographical distribution in Asturias, which largely differ from other areas of Spain. Our findings may help design a first step recurrent mutation panel for screening high-risk breast and/or ovarian cancer families from this specific area. (Source: BMC Cancer)
Source: BMC Cancer - May 17, 2013 Category: Cancer & Oncology Authors: Pilar BlayIñigo SantamaríaAna PitiotMaría LuqueMarta AlvaradoAna LastraYolanda FernándezÁngeles ParedesJosé FreijeMilagros Balbín Source Type: research

Alginate beads as a tool to handle, cryopreserve and culture isolated human primordial/primary follicles.
Conclusions Our results show that 1.4M ME2SO yields better preservation of isolated PF viability after thawing and 7 days of IVC than 1.5M EG. Alginate constitutes an easy, safe hydrogel matrix to handle and cryopreserve isolated human follicles using ME2SO as a CPA. PMID: 23688636 [PubMed - as supplied by publisher] (Source: Cryobiology)
Source: Cryobiology - May 17, 2013 Category: Biology Authors: Camboni A, Van Langendonckt A, Donnez J, Vanacker J, Dolmans MM, Amorim CA Tags: Cryobiology Source Type: research

Overexpression of CD147 in ovarian cancer is initiated by the hypoxic microenvironment.
Abstract Ovarian cancer is a lethal malignant tumor characterized by activated invasion, distant metastasis, anti-cancer drug resistance, angiogenesis and metabolism. CD147, an extracellular matrix metalloproteinase inducer, is overexpressed in most ovarian tumors and plays an important role in the progression of ovarian cancer and other malignant tumors. However the factor(s) initiating this overexpression is unknown. Because of rapid reproduction and their hypoxic microenvironment, malignant tumors use glycolysis for energy, and lactic acid produced is harmful to the cells. For survival, excessive lactate needs t...
Source: Cell Biology International - May 17, 2013 Category: Cytology Authors: Yang H, Zou W, Chen B Tags: Cell Biol Int Source Type: research

Progression-Free Survival Data for Investigational Afatinib and Nintedanib
Nintedanib is being evaluated in various solid tumors – including advanced NSCLC, ovarian cancer, liver cancer (hepatic cell carcinoma), kidney cancer (renal cell carcinoma) and colorectal cancer.05/16/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 16, 2013 Category: Cancer & Oncology Source Type: news

Will insurance cover genetic testing, preventive surgery?
Women who discover they carry a hereditary gene mutation that dramatically increases their risk of breast and ovarian cancers face big decisions and the possibility of tens of thousands of dollars in medical costs. (Source: WDSU.com - Health)
Source: WDSU.com - Health - May 16, 2013 Category: Consumer Health News Source Type: news

How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter
ConclusionsOncologists provide women with information on their disease status, their treatment options and the side effects of treatment. The oncologists use perceptions to determine what information and how to provide information. The question this paper raises is whether the oncologist's perceptions reflect the individual patient's information and decision‐making needs. (Source: Health Expectations)
Source: Health Expectations - May 16, 2013 Category: Health Management Authors: Lorraine M. Elit, Cathy Charles, Amiram Gafni, Jennifer Ranford, Sara Tedford‐Gold, Irving Gold Tags: Original Article Source Type: research

Angelina Jolie Will Have Ovaries Removed to Lower Chances of Cancer: Report
Title: Angelina Jolie Will Have Ovaries Removed to Lower Chances of Cancer: ReportCategory: Health NewsCreated: 5/15/2013 2:36:00 PMLast Editorial Review: 5/16/2013 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 16, 2013 Category: Cancer & Oncology Source Type: news

Angelina Jolie to remove ovaries: What are options for women at increased risk?
People who have defective BRCA genes have a 20 to 40 percent chance of developing ovarian cancer in their lifetime (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 15, 2013 Category: Consumer Health News Source Type: news

Angelina Jolie Will Have Ovaries Removed to Lower Chances of Cancer: Report
Actress has already had double mastectomy due to gene linked to high risk for breast, ovarian cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 15, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Research, News, Source Type: news

Ovarian cancer fall sped up as hormone use dropped
NEW YORK (Reuters Health) - Ovarian cancer rates in the U.S. began to decline faster in 2002 around the time many older women went off hormone replacement therapy, according to a new study. (Source: Reuters: Health)
Source: Reuters: Health - May 15, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Angelina's breasts and the public ownership of body parts | Dean Burnett
Criticism of Angelina Jolie's decision to have a double mastectomy suggests members of the public feel they have a claim to the body parts of other peopleAngelina Jolie recently had a double mastectomy after she found she had the gene predisposing her to breast and ovarian cancer. After going public, she received a lot of praise for her decision. However, as she is a celebrity, and this is 2013 so the internet exists to ensure that no examples of mindless idiocy gets ignored, she also received criticism. A lot of this criticism seemed to be from men who were apparently fans of her breasts and weren't happy about them being...
Source: Guardian Unlimited Science - May 15, 2013 Category: Science Authors: Dean Burnett Tags: Psychology Blogposts Genetics Biology Health guardian.co.uk Body image Society Women Angelina Jolie Life and style Celebrity Science Source Type: news

Don't Tell Me Anything Negative
I looked after one of my partner’s patients who is approaching death from advanced, refractory ovarian cancer. She asked me not to talk about anything negative with her. We can’t really make any decisions without discussing negative things. Should I just remain silent about them at her request? (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
(University of Pennsylvania School of Medicine) In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 15, 2013 Category: Global & Universal Source Type: news

Fish in the diet: A review
Summary Fish plays a useful role in a healthy and balanced diet, and its consumption has long been associated with several health benefits. Fish provides a variety of nutrients, including protein and long‐chain omega‐3 polyunsaturated fatty acids (n‐3 PUFAs), as well as micronutrients including selenium, iodine, potassium, vitamin D and B‐vitamins. Intakes of some of these micronutrients, including iodine and vitamin D, are low in some population groups in the UK, which makes fish a valuable contributor to intakes of these. The long‐chain n‐3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), pres...
Source: Nutrition Bulletin - May 15, 2013 Category: Nutrition Authors: E. Weichselbaum, S. Coe, J. Buttriss, S. Stanner Tags: REVIEW Source Type: research

Video: Angelina Jolie's mastecomy: Should you get the BRCA gene test?
CBS News medical contributor Dr. Holly Phillips explains the process and pros and cons of genetic testing for women concerned about their risk of developing breast or ovarian cancer. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 14, 2013 Category: Consumer Health News Source Type: news

BRCA test leads Angelina Jolie to get double mastectomy: Who should get tested?
37-year-old actress said she carries a "faulty" BRCA1 gene, which sharply increases her risk for developing breast and ovarian cancer (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 14, 2013 Category: Consumer Health News Source Type: news

Angelina Jolie Has Double Mastectomy Because Of 87% Breast Cancer Risk
Actress Angelina Jolie, who carries a mutation in her BRCA1 gene, announced that she has had a double mastectomy. Women who carry a BRCA1 or BRCA2 mutation have a significantly higher risk of developing breast and ovarian cancers. According to Angelina Jolie, her lifetime risk of developing breast cancer before having her breasts surgically removed was 87%. Having the BRCA1 mutation also means a 50% lifetime risk of ovarian cancer. According to scientists at the Johns Hopkins Kimmel Cancer Center, carrying the BRCA1 mutation may also be linked to other cancers... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 14, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Jolie has double mastectomy
Actress Angelina Jolie announced in a New York Times op-ed article on Wednesday that she underwent a preventive double mastectomy after learning she carries the BRCA1 gene, which sharply increases her risk of developing breast cancer and ovarian cancer. (Source: CNN.com - Health)
Source: CNN.com - Health - May 14, 2013 Category: Consumer Health News Source Type: news

Angelina Jolie's surgery to 'reduce breast cancer risk'
Writing in the New York Times, actress Angelina Jolie has announced that she has recently undergone a double mastectomy (where both breasts are surgically removed) followed by breast reconstruction surgery. She writes that this is because genetic testing revealed she had a 87% chance of developing breast cancer in later life, as well as a 50% risk of ovarian cancer. This means she took a decision to have ‘preventative surgery’. Jolie explained: "I decided to be proactive and to minimise the risk as much as I could. I made a decision to have a preventative double mastectomy. "Cancer is still a word that strike...
Source: NHS News Feed - May 14, 2013 Category: Consumer Health News Tags: Cancer QA articles Source Type: news

Induction of Apoptosis and Inhibition of Angiogenesis by PEGylated Liposomal Quercetin in Both Cisplatin-Sensitive and Cisplatin-Resistant Ovarian Cancers
(Source: Journal of Biomedical Nanotechnology)
Source: Journal of Biomedical Nanotechnology - May 14, 2013 Category: Nanotechnology Authors: Long, QidaXie, YaoHuang, YanqingWu, QinjieZhang, HechengXiong, ShaoquanLiu, YingweiChen, LijuanWei, YuquanZhao, XiaGong, Changyang Tags: Articles Source Type: research

Surgery for a Bowel Obstructio
A large bowel obstruction is a potential complication of advanced cancers of the colon, ovaries or stomach. Learn more about the symptoms, treatment and risks of this blockage. (Source: About.com Colon Cancer)
Source: About.com Colon Cancer - May 14, 2013 Category: Cancer & Oncology Authors: coloncancer.guide at about.com Tags: health Source Type: news

Current MR Imaging Lipid Detection Techniques for Diagnosis of Lesions in the Abdomen and Pelvis [Gastrointestinal Imaging]
This article reviews MR imaging fat detection techniques and discusses lesions in the abdomen and pelvis that can be readily diagnosed by using these techniques. Traditional fat detection methods include inversion-recovery and chemically selective fat-suppression pulse sequences, with the former being less sensitive to field heterogeneity and less tissue specific than the latter. Chemical shift–based sequences, which exploit the inherent resonance frequency difference between lipid and water to depict intracytoplasmic fat, have great utility for evaluating hepatic steatosis and lesions such as adrenal and hepatic ade...
Source: Radiographics recent issues - May 14, 2013 Category: Radiology Authors: Pokharel, S. S., Macura, K. J., Kamel, I. R., Zaheer, A. Tags: Magnetic Resonance Imaging, Gastrointestinal Radiology Gastrointestinal Imaging Source Type: research

Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium
Conclusions Our results support the use of BRCAPRO and BOADICEA for decision making regarding genetic testing for BRCA1/2 mutations. However, model calibration has to be improved for this population. eCLAUS should not be used for estimating mutation carrier probabilities in clinical settings. Whenever possible, breast tumour molecular marker information should be taken into account. (Source: Journal of Medical Genetics)
Source: Journal of Medical Genetics - May 13, 2013 Category: Genetics & Stem Cells Authors: Fischer, C., Kuchenbacker, K., Engel, C., Zachariae, S., Rhiem, K., Meindl, A., Rahner, N., Dikow, N., Plendl, H., Debatin, I., Grimm, T., Gadzicki, D., Flottmann, R., Horvath, J., Schrock, E., Stock, F., Schafer, D., Schwaab, I., Kartsonaki, C., Mavaddat Tags: Reproductive medicine, Breast cancer, Drugs: endocrine system Cancer genetics Source Type: research

Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2
This study showed no increased risk of ovarian cancer in families that tested negative for BRCA1/2 or were untested. These data help counselling women from BRCA1/2 negative families with breast cancer that their risk of invasive ovarian cancer is not higher than the general population. (Source: Journal of Medical Genetics)
Source: Journal of Medical Genetics - May 13, 2013 Category: Genetics & Stem Cells Authors: Ingham, S. L., Warwick, J., Buchan, I., Sahin, S., O'Hara, C., Moran, A., Howell, A., Evans, D. G. Tags: Breast cancer Cancer genetics Source Type: research

Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer
Abstract Epithelial ovarian cancer (EOC) is hallmarked by a high degree of heterogeneity. To address this heterogeneity, a classification scheme was developed based on gene expression patterns of 1538 tumours. Five, biologically distinct subgroups — Epi‐A, Epi‐B, Mes, Stem‐A and Stem‐B — exhibited significantly distinct clinicopathological characteristics, deregulated pathways and patient prognoses, and were validated using independent datasets. To identify subtype‐specific molecular targets, ovarian cancer cell lines representing these molecular subtypes were screened against a genome‐wide shRNA library. F...
Source: EMBO Molecular Medicine - May 13, 2013 Category: Molecular Biology Authors: Tuan Zea Tan, Qing Hao Miow, Ruby Yun‐Ju Huang, Meng Kang Wong, Jieru Ye, Jieying Amelia Lau, Meng Chu Wu, Luqman Hakim Bin Abdul Hadi, Richie Soong, Mahesh Choolani, Ben Davidson, Jahn M. Nesland, Ling‐Zhi Wang, Noriomi Matsumura, Masaki Mandai, Ikuo Tags: Research Article Source Type: research